Recent Updates
Recently added Catalysts
OKYO Positive Sentiment

OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London

Thursday, November 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: OKYO Pharma Limited will participate in the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026. The leadership team will be available for one-on-one investor meetings during the event. The company is developing therapies for neuropathic corneal pain and has enrolled first patients in its Phase 3 NEPTUNE trial.
Price reaction · baseline $1.42 (2026-11-11 close) · hit pre-market · clean, no other OKYO news in the window
day 0 close
-1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a major healthcare conference
  • Opportunity for one-on-one investor meetings
  • Lead candidate urcosimod in Phase 3 trial

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
4.8%
average across 4 past catalysts
Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeks
Phase 3 · Neuropathic Corneal Pain

Full Press Release Details

LONDON and NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that it will participate at the 2026 Jefferies Global Healthcare Conference in London, United Kingdom taking place from November 16–19, 2026.
The Leadership team will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Jefferies representative.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. Lead candidate, urcosimod for neuropathic corneal pain (NCP), recently announced first patients enrolled in Phase 3 NEPTUNE trial. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

Investor inquiries or meeting requests:

OKYO Pharma Ltd Paul Spencer Business Development and Investor Relations +44 (0) 207 495 2379 Email: ir@okyopharma.com

Frequently Asked Questions

When is the Jefferies Global Healthcare Conference?

The conference takes place from November 16-19, 2026.

What will OKYO Pharma do at the conference?

OKYO Pharma will participate and hold one-on-one investor meetings.

What is OKYO Pharma's lead candidate?

The lead candidate is urcosimod for neuropathic corneal pain.

What trial is urcosimod currently in?

Urcosimod is in the Phase 3 NEPTUNE trial.

ShareAdd on Google
Tags: OKYO OKYO Pharma Jefferies Conference neuropathic corneal pain Phase 3 trial investor meetings
Last updated: Nov 12, 2026

Biotech snapshot

Lead asset
Urcosimod is a preservative-free product; supplied in unit dose ampoules; administered QID for 12-weeksPhase 3
Neuropathic Corneal Pain →

Catalyst track record

+14%
best trade around OKYO's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for OKYO.

See every catalyst's timing & PoA →